Multitude Therapeutics

Antibody drug conjugate
#Adcendo #Antibody drug conjugate (ADC) #Cancer research #Multitude Therapeutics

Agreement facilitates differentiated ADC targeting Tissue Factor 

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.  TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More

#Cancer Research #News